NEWS
-
August 15, 2024
Biosimilars Forum Calls on CMS to Support Lower-Cost Biosimilars and Increase Access for Patients
-
July 24, 2024
The Biosimilars Forum Supports House Committee on Oversight and Accountability Probe Into the PBM Monopoly
-
July 9, 2024
Biosimilars Forum Calls for Reform of the PBM Monopoly
-
March 20, 2024
Biosimilars Forum Announces Support for Increasing Access to Biosimilars Act
-
March 14, 2024
Biosimilars Forum Urges Congress to Support Free Market Competition and Lower Prescription Drug Prices for Patients by Reforming Pharmacy Benefit Managers
-
January 24, 2024
Biosimilars Forum Welcomes Teva as Newest Member
-
January 10, 2024
Biosimilars Forum Welcomes Biocon Biologics as Newest Member
-
November 30, 2023
Julian Malasi Member Spotlight
-
November 16, 2023
Affordable prescription drugs exist — why can’t more patients access them?
-
November 3, 2023
Biosimilars Forum Supports Senate Finance Committee Legislative Discussion Draft Promoting Biosimilars
-
November 2, 2023
Biosimilars Forum Announces Support for Bipartisan Interchangeability Legislation
-
October 17, 2023
Biosimilars Forum Welcomes Meitheal Pharmaceuticals as Newest Member
-
October 10, 2023
Biosimilars Forum Welcomes Amneal as Newest Member
-
August 30, 2023
Biosimilars Forum Statement on CMS Announcement of Drug Negotiation List
-
August 7, 2023
Biosimilars Forum Scientific Publication Identifies Pathway to Streamlined Development for Biosimilars
-
July 25, 2023
Biosimilars Forum Applauds Boehringer Ingelheim for Launch of Cyltezo®
-
July 10, 2023
Biosimilars Forum Congratulates Fresenius Kabi for Launch of IDACIO®
-
July 6, 2023
Biosimilars Forum Applauds Sandoz for Launch of Hyrimoz®
-
July 6, 2023
Biosimilars Forum Applauds Organon and Samsung Bioepis for Launch of HADLIMA™
-
July 5, 2023
Biosimilars Forum Applauds Coherus for Launch of YUSIMRY™
-
June 30, 2023
Delivering on a Watershed Moment for Biosimilars and Patients
-
April 10, 2023
Biosimilars Key to Lowering Healthcare and Prescription Drug Costs, According to Employers
-
March 30, 2023
Biosimilars Forum Applauds the U.S. Senate Finance Committee for Holding PBMs Accountable for Prioritizing Profits over Patients
-
March 3, 2023
Biosimilars Forum Applauds Congressman Hudson for Supporting Biosimilars Through Shared Savings Legislation
-
January 31, 2023
The Biosimilars Forum Calls on Decisionmakers to Deliver on Humira Biosimilars
-
November 10, 2022
Dorothy McCabe Member Spotlight
-
November 3, 2022
Biosimilars Forum Wins Global Biosimilars Industry Partner of the Year at Global Generics & Biosimilars Awards
-
October 4, 2022
Biosimilars Forum Applauds CMS Biosimilars Measure
-
October 4, 2022
Inflation Reduction Act – ASP+8 Biosimilars Payment Increase
-
September 20, 2022
ASP +8: CMS Releases Biosimilars Information
-
August 6, 2022
Biosimilars Forum Warns Limited Negotiation Policies Will Stymie Innovation
-
July 28, 2022
Hillel Cohen Member Spotlight
-
July 21, 2022
The Biosimilars Forum Launches Updated Website Content
-
July 14, 2022
Rebecca Mandell Member Spotlight
-
June 22, 2022
The Biosimilars Forum Welcomes Legislation to Hold PBMs Accountable for Unfair Practices
-
June 21, 2022
Rachel Turow Member Spotlight
-
June 16, 2022
Brian Lehman Member Spotlight
-
June 7, 2022
The Biosimilars Forum Commends FTC for Probe into PBMs
-
June 6, 2022
Biosimilars Forum Welcomes Fresenius Kabi
-
May 17, 2022
Tiffany Fletcher Member Spotlight
-
April 6, 2022
Biosimilars Forum Letter to Senate HELP Committee on FDA User Fee Agreements
-
March 31, 2022
HHS Inspector General Report: Biosimilars Could Generate Significant Medicare Part D Savings
-
March 9, 2022
Biosimilars Forum Executive Director to Discuss Current Biosimilars Landscape at World Biosimilars Congress
-
March 2, 2022
The Biosimilars Forum Calls on President Biden to Incentivize Biosimilars to Lower Prescription Drug Costs
-
March 1, 2022
Biosimilars Forum Welcomes HHS Inspector General Study on Biosimilars in Medicare Part B
-
February 22, 2022
Report Highlights Employer Savings from Increased Employee Access to Biosimilars
-
February 15, 2022
The Biosimilars Forum Congratulates Dr. Robert Califf on His Confirmation as FDA Commissioner
-
February 3, 2022
Biosimilars Forum Supports the Negotiated BsUFA III Agreement in Capitol Hill Testimony
-
January 31, 2022
Juliana M. Reed Named Executive Director of the Biosimilars Forum
-
November 12, 2021
The Biosimilars Forum Congratulates Robert Califf on His Nomination for FDA Commissioner
-
October 26, 2021
Biosimilars Forum to Congress: Incentivize Biosimilars in Build Back Better Act
-
October 21, 2021
Biosimilars Forum Member Spotlight: 5 Questions for Samsung Bioepis
-
October 20, 2021
First Biosimilar to Treat Eye Disease Gains FDA Approval
-
October 20, 2021
Biosimilars Forum Applauds FDA’s Approval of Second Interchangeable Biosimilar
-
October 13, 2021
New Report Finds Biosimilars Could Save States Billions of Dollars Annually
-
September 20, 2021
Senator Wyden, fulfill your promise to lower drug costs for Oregonians by increasing access to next generation generics known as biosimilars
-
September 20, 2021
Senator Carper, fulfill your promise to lower drug costs for Delawareans by increasing access to next generation generics known as biosimilars
-
September 9, 2021
Biden Administration’s Plan to Lower Prescription Drug Prices Supports Biosimilar Competition, which will Decrease Drug Costs
-
August 12, 2021
President Biden’s Plan to Lower Drug Prices Highlights Need for Competition from Biosimilars
-
August 11, 2021
Biosimilars Forum Member Spotlight: 5 Questions for Organon
-
July 29, 2021
FDA’s Approval of First Interchangeable Biosimilar Product Paves Way for Lower Health Care Costs for Patients
-
July 15, 2021
Food & Drug Administration Takes Strong Enforcement Action Against Biosimilar Misinformation
-
July 9, 2021
President Biden’s Executive Order to Support Biosimilar Drugs Will Provide Lower Cost Options for Patients
-
July 8, 2021
Morning Consult: Expanding Access to Biosimilars Has Bipartisan Support. But Movement on Legislation Hangs in the Balance of the Drug Pricing Debate
-
June 30, 2021
Biosimilars Forum Member Spotlight: 6 Questions for Coherus
-
June 24, 2021
Organon Joins Biosimilars Forum
-
June 21, 2021
Lowering Prices with Biosimilars: ASP+8: Stakeholder Meeting Round-Up
-
June 18, 2021
It’s time we fulfill the ACA’s promise to broaden access to lower-cost drugs
-
June 17, 2021
The Biosimilars Forum Applauds SCOTUS Decision to Uphold ACA and US Pathway for Biosimilar Approval
-
June 14, 2021
New Report Shows Biosimilars Significantly Lowered Prices of All Biologics
-
May 18, 2021
House Oversight Committee Spotlights Anticompetitive Practices Blocking Access to Lower Cost Biosimilars
-
April 30, 2021
Senators Cornyn and Bennet Introduce Bipartisan Legislation to Incentivize Biosimilars, Lower Cost for Seniors
-
April 28, 2021
Biosimilars Forum Calls for Bipartisan Policies That Lower Drug Prices on Expensive Biologics Ahead of President Biden’s Joint Session of Congress Address
-
April 27, 2021
Congressmen Tonko and Gibbs Introduce Bipartisan Legislation to Increase Transparency and Use of Biosimilars in Medicare Plans
-
April 26, 2021
President Biden Signs the Advancing Education on Biosimilars Act Into Law
-
April 23, 2021
Congressmen Kurt Schrader and Adam Kinzinger Introduce Bipartisan Legislation to Lower Drug Costs, Incentivize Biosimilars
-
April 14, 2021
Congress Passes Legislation to Lower Health Care Costs Through Bolstering Biosimilars Education
-
April 14, 2021
Biosimilars Forum Member Spotlight: 5 Questions for Viatris
-
April 5, 2021
Value of Biosimilars in Women’s Health: HealthyWomen Roundtable Series Roundup
-
March 23, 2021
The Biosimilars Forum Statement on the 11-Year Anniversary of the ACA and BPCIA
-
March 18, 2021
Biosimilars Forum Statement on The Confirmation of Xavier Becerra As U.S. Secretary of Health And Human Services
-
March 18, 2021
New Economic Report Demonstrates How Biosimilar Competition Lowers Prices
-
November 30, 2020
Viatris Inc. Joins Biosimilars Forum
-
November 23, 2020
The Biosimilars Forum Announces Meaghan Rose Smith as Executive Director
-
November 19, 2020
Biosimilars Forum Statement at FDA’s BsUFA III Kick-off Meeting
-
October 6, 2020
Biosimilars Could Generate $100 Billion in Savings Over Next Five Years, New Report Finds
-
September 21, 2020
U.S. Taxpayers and the Health Care System At-Large Have Lost out on Nearly $20 Billion in Savings Since 2018
-
September 10, 2020
The Biosimilars Forum Filed Comment on FDA’s Notice Detailing the Impact of Disclosure Statements in Biosimilar Promotional Materials
-
July 31, 2020
ICYMI: Experts Detail How Shared Savings Model for Biosimilars Could Provide Savings for Seniors, Patients and Medicare
-
July 31, 2020
MedPac: Top 10 Most Expensive Medicare Part B Drugs are Originator Biologics
-
July 24, 2020
Trump Administration’s Drug Plan Must Include Biosimilars to Lower Costs for Seniors and Medicare
-
July 14, 2020
ICYMI: House Appropriators Encourage CMS to Support Biosimilars; Experts Point to Biosimilars to Help Lower Drug Costs, Call on Congress and Administration to Act
-
July 1, 2020
The Biosimilars Forum Applauds Senators Cornyn and Bennet’s Introduction of Legislation to Lower Health Costs by Supporting Biosimilars
-
June 22, 2020
The Biosimilars Forum To Provide Comment at FDA’s Annual Meeting on the Biosimilar User Fee Program
-
May 28, 2020
Bringing Down Federal Spending: A Biosimilars Shared Savings Model To Lower Health Care Costs
-
May 27, 2020
Robust Biosimilars Market Could Save U.S. Taxpayers $7 Billion Annually, New Analysis Finds
-
May 21, 2020
AMA: U.S. Health Insurance Plans Prefer Brand Biologics Twice as Often as Lower-Cost Biosimilars
-
April 30, 2020
ICYMI: After Congress Approved $3 Trillion in Spending Amid the COVID-19 Pandemic, Biosimilars Can Reduce Health Care Costs for Employers and the U.S. Health Care System
-
April 27, 2020
ICYMI: Expert Encourage Increasing Biosimilar Use to Lower Health Care Costs; Study Finds Biosimilars Could Lower Employers Insurance Costs
-
March 31, 2020
Self-Insured Employers Could Have Saved Up to $1.4 Billion in 2018 with Lower-Cost Biosimilars
-
March 13, 2020
ICYMI: This Week, HHS Secretary Azar, Congressman Burgess, Physicians and Patients Pointed to Biosimilars to Save Seniors and Taxpayers Money; Congress Introduces Two Bills to Lower Costs with Biosimilars
-
March 13, 2020
The Biosimilars Forum Applauds Senators McSally (R-AZ) and Jones (D-AL) Introduction of S. 3466, the ACCESS for Biosimilars Act of 2020
-
March 11, 2020
The Biosimilars Forum Supports Congressmen Cardenas, Hudson, Fitzpatrick, & Craig Introduction of H.R. 6179 — Lowering Costs For Taxpayers and Medicare Seniors with Biosimilars
-
March 5, 2020
The Importance of Dispelling Misinformation About Biosimilar Therapies
-
February 10, 2020
White House Budget Proposal Recognizes Urgent Need to Increase Patient Access to Lower-Cost Biosimilars
-
February 4, 2020
President Trump Can Look to Biosimilars to Keep Promise of Saving Americans Billions in Health Care Costs
-
February 3, 2020
Biosimilars Forum Praises FTC and FDA Action to Fight Anticompetitive Behaviors Blocking Access to Lower Cost Biosimilars
-
December 12, 2019
Biosimilars Forum Statement on Policies Supporting Biosimilar Uptake in Canadian Market
-
December 12, 2019
Biosimilars Forum Congratulates Dr. Stephen Hahn on Confirmation to Lead the Food and Drug Administration (FDA)
-
November 25, 2019
ICYMI: Biosimilars are a Recognized, Bipartisan Solution to Lowering Health Care Costs; Nominee for FDA Commissioner Reinforces Need to Increase Access for Biosimilars
-
November 20, 2019
Biosimilars Forum Statement Regarding Nomination of Dr. Stephen Hahn as Next Commissioner of the Food and Drug Administration (FDA)
-
November 13, 2019
The Biosimilars Forum Reacts to CMS Report on Increased Medicare Premiums for Seniors
-
November 11, 2019
ICYMI: Trump Administration’s Joe Grogan Recognizes Need for Biosimilar Incentives to Help Lower Healthcare Costs
-
October 18, 2019
The Biosimilars Forum Applauds Launch of New FDA Performance Dashboard
-
October 9, 2019
The Biosimilars Forum Applauds Congressmen Paul Tonko (D-NY) and Bob Gibbs (R-OH) for Introducing Legislation Mandating a CMS Star Ratings Program for Biosimilars
-
October 3, 2019
President Trump Can Easily Reduce Health Care Costs for U.S. Seniors and Taxpayers by Increasing Biosimilar Use
-
October 3, 2019
New Analysis Confirms All 50 States Stand to Benefit from Increased Use of Biosimilars
-
October 1, 2019
The Biosimilars Forum Applauds Congressmen Scott Peters, Pete King and Anthony Brindisi For Introducing $0 Copay Biosimilars Legislation for Medicare Part B
-
September 20, 2019
The Biosimilars Forum Applauds Bipartisan Introduction of the BIOSIM Act
-
September 19, 2019
House Energy & Commerce Committee Hearing Highlights How Biosimilars Can Save Patients Money
-
September 9, 2019
Biosimilars Forum’s Public Letter In Response to Anti-Biosimilars Op-Ed
-
August 22, 2019
New Analysis Encourages Employer Engagement to Help Realize Significant Savings Potential of Biosimilars
-
July 30, 2019
Forum Statement in Response to Senate Finance Committee Advancing its Drug Pricing Package
-
July 25, 2019
Forum Statement on Senate Finance Provision and New Amendment That Could Save Taxpayers and Seniors Billions
-
July 23, 2019
Senate Finance Provision Increasing ASP for Biosimilars Could Unlock Billions in Savings for Patients and Taxpayers
-
July 11, 2019
New Analysis Confirms Increased Use of Biosimilars Can Save U.S. Up to $71 Billion Over a Decade
-
June 20, 2019
Health Experts Agree Increasing Biosimilar Use Can Help Reduce Rising Drug Costs for Patients
-
May 29, 2019
Biosimilars Forum Announces Support for Policies that Would Save Taxpayers and Seniors Billions
-
May 23, 2019
The Biosimilars Forum Commends Senate HELP Committee’s Effort to Educate Patients and Providers on Biosimilars
-
May 10, 2019
The Biosimilars Forum Comments on FDA’s New Interchangeability Guidance for Industry
-
March 19, 2019
Significant Healthcare Savings Possible if U.S. Cultivates a Robust Biosimilars Market
-
March 7, 2019
The Biosimilars Forum Disagrees with the Food and Drug Administration’s Decision on Naming of Biologic Medicines
-
March 6, 2019
The Biosimilars Forum Recognizes Commissioner Gottlieb’s Leadership Supporting a Strong Biosimilars Market in the U.S.
-
February 26, 2019
Removing 340B Pass-Through Would be Detrimental to US Healthcare Savings
-
February 26, 2019
The Biosimilars Forum Urges Senate Finance Committee to Seek Meaningful Biosimilars Reform
-
February 12, 2019
The Biosimilars Forum Objects to Consolidate Billing of Biosimilars
-
February 1, 2019
The Biosimilar Forum Recognizes Leah Christl’s Departure from FDA
-
January 31, 2019
The Biosimilars Forum Applauds HHS Proposal to Target Costly Rebates Structure Blocking Patients from Biosimilars and Savings
-
December 13, 2018
The Biosimilars Forum Commends FDA for Commitment to Increase Patient Access to Biosimilars
-
December 4, 2018
Biosimilars Forum Statement on Citizen Petition to the Food and Drug Administration
-
December 3, 2018
Biosimilars Forum Announces Launch of Biosimilars Roundtable
-
October 10, 2018
New White Paper Finds Biosimilars Could Drive Greater Value Beyond Price for Healthcare System
-
August 9, 2018
Biosimilars Forum Statement on CMS Announcement Regarding Medicare Advantage
-
July 18, 2018
Biosimilars Forum Applauds Biosimilars Action Plan Released by FDA Commissioner Scott Gottlieb
-
July 16, 2018
Biosimilars Forum Submits Comments on HHS Blueprint to Lower Drug Prices
-
July 12, 2018
Biosimilars Forum Commends FDA Commissioner For Raising Awareness Of Biosimilars
-
July 9, 2018
Biosimilars Forum Convenes Stakeholder Groups to Discuss Advancing Biosimilars
-
June 27, 2018
Biosimilars Forum Releases Position on Non-Medical Switching
-
June 21, 2018
Biosimilars Forum Applauds FDA Decision to Reevaluate Draft Guidance
-
May 16, 2018
Biosimilars Forum Applauds Approval of 10th Biosimilar in United States
-
May 11, 2018
Biosimilars Forum Encouraged by Trump Administration’s Support for Biosimilars
-
March 9, 2018
Biosimilars Forum Encouraged By Food And Drug Administration Commissioner’s Support of Biosimilars
-
February 22, 2018
Biosimilars Forum Opposes Efforts to Prohibit Biosimilars From Receiving Pass-Through Payment Status
-
February 12, 2018
Biosimilars Forum Supports Inclusion of Biosimilars in the Medicare Coverage Gap Discount Program
-
November 2, 2017
Biosimilars Forum Applauds CMS Decision to Reverse Existing Rule on Biosimilar Reimbursement Policy
-
October 24, 2017
Biosimilars Forum Applauds Food and Drug Administration on New Educational Program Promoting Safety and Effectiveness of Biosimilars
-
September 14, 2017
Biosimilars Forum Opposes Current CMS Rule That Would Adversely Affect Biosimilars Development in the U.S.; Submits Comments on Appropriate Biosimilar Reimbursement Policy
-
August 19, 2017
Biosimilars Forum Applauds President Trump for Signing the FDA Reauthorization Act
-
August 3, 2017
Biosimilars Forum Applauds Senate Passage of the FDA Reauthorization Act
-
July 19, 2017
Biosimilars Forum Makes Available Xcenda Study on Budgetary Impact of Biosimilars Coding
-
July 14, 2017
Biosimilars Forum Applauds CMS Decision to Revisit Biosimilars Coding Policy
-
May 12, 2017
Biosimilars Forum Applauds Senator Roberts, Reps. Barton, Eshoo for Leadership on Medicare Policy on Biosimilar Coding
-
May 11, 2017
Biosimilars Forum Statement Regarding Newly Released EMA Information Guide on Biosimilars For Healthcare Professionals
-
May 10, 2017
Biosimilars Forum Statement Regarding Confirmation of Dr. Scott Gottlieb as Commissioner of the Food and Drug Administration
-
May 3, 2017
Biosimilars Forum Submits Comments in Response to FDA’s Draft Guidance for Industry on Interchangeability for Biosimilar Products
-
March 14, 2017
Biosimilars Forum Congratulates Seema Verma on Confirmation as Next Administrator of the Centers for Medicare and Medicaid Services
-
March 13, 2017
Biosimilars Forum Statement Regarding Nomination of Dr. Scott Gottlieb as Next Commissioner of the Food and Drug Administration
-
March 2, 2017
Past President of Biosimilars Forum Testifies before Congress Regarding BsUFA
-
January 17, 2017
Biosimilars Forum Statement Regarding FDA’s Draft Guidance for Industry on Interchangeability for Biosimilar Products
-
January 12, 2017
Biosimilars Forum Statement Regarding FDA’s Final Guidance on Nonproprietary Naming of Biosimilar Products
-
January 11, 2017
Biosimilars Forum Statement Regarding the CMS’ Treatment of Biosimilars Under the Medicaid Drug Rebate Program
-
November 1, 2016
Awareness of Biosimilars Among U.S. Specialty Physicians is High but New Survey Identifies Five Major Knowledge Gaps
-
October 20, 2016
Biosimilars Forum Submits comments on FDA Biosimilar Biological Product Reauthorization Performance Goals and Procedures Fiscal Years 2018 through 2022
-
September 16, 2016
Biosimilars Forum Applauds Outcome of BsUFA Negotiations; Pleased to Have Played Important Role in Decision-Making
-
June 3, 2016
Biosimilars Forum Submits Comments in Response to FDA Draft Industry Guidance on Labeling for Biosimilar Products
-
March 31, 2016
Biosimilars Forum Issues Statement on FDA Draft Industry Guidance on Labeling for Biosimilar Products
-
March 16, 2016
Biosimilars Forum Issues Statement on Proposed Part B Drug Payment Model
-
February 9, 2016
Biosimilars Forum Statement: FDA Arthritis Advisory Committee Meeting for Biosimilar to Remicade (Infliximab), Submitted by Celltrion, Inc.
-
February 4, 2016
Biosimilars Forum Issues Statement Regarding House Energy & Commerce, Subcommittee on Health Biosimilars Hearing, Launch of New Biosimilars Education Initiative
-
February 1, 2016
Biosimilars Forum Launches “Partnership for Biosimilars Education and Access”
-
November 5, 2015
EPIRUS Biopharmaceuticals Joins Biosimilars Forum to Help Educate Patients and Health Care Providers on Importance of Biosimilars
-
October 30, 2015
Biosimilars Forum Disappointed with CMS Final Rule on Biosimilar Payment and Coding
-
October 27, 2015
Biosimilars Forum Comments on FDA Naming Guidance
-
October 8, 2015
Biosimilars Forum Applauds Senators Roberts, Carper for Leadership on Proposed Medicare Rule on Biosimilar Coding
-
September 8, 2015
Biosimilars Forum Issues Comments for CMS Proposed Rule on Biosimilar Payment and Coding
-
September 3, 2015
Biosimilars Forum Statement on the Introduction of Biosimilars in the United States
-
August 27, 2015
Forum Statement on Proposed FDA Guidance on Naming of Biological Products
-
August 5, 2015
Biosimilars Forum Applauds Reps. Barton, Eshoo for Leadership on Proposed Medicare Rule on Biosimilar Coding
-
July 9, 2015
Biosimilars Forum Expresses Concern with CMS Proposed Rule on Biosimilar Payment and Coding
-
May 5, 2015
Biosimilars Forum Statement Regarding the Need for Appropriate Coding for Biosimilars
-
May 5, 2015
New Forum Launches to Expand Access to Biosimilar Medicines, Improve Health Care